Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

Stock Information for CytoMed Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CytoMed Therapeutics Limited

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95%
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic ?? T Cells in Acute Myeloid Leukemia 
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.